December 2024. The FDA warned that fezolinetant can cause ‘rare but serious liver injury,’ based on a report of a patient with elevated liver blood test values and signs and symptoms of liver injury after taking fezolinetant for about 40 days. The FDA recommends that before starting, and during, treatment with fezolinetant, liver function tests should be performed (serum ALT, serum AST, serum ALP, and serum bilirubin (total and direct)).
- TRADE NAME: Veozah (Astellas)
- INDICATIONS:
Indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. A non-hormonal drug used to treat hot flashes or night sweats.
- CLASS: Neurokinin 1 receptor antagonist
- HALF-LIFE: 9.6 hours
- FDA APPROVAL DATE: 05/12/2023
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Page last updated 08/21/2026
